Every 8-K that UnitedHealth Group Incorporated (UNH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow UNH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNH filings page.
UnitedHealth Group Inc. (UNH) announced that senior leaders will participate in an interview-format discussion at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, beginning at 8:00 a.m. Eastern Time. Topics will include the company’s strategy, market positions, recent results and expectations for its end markets.
A live audio webcast of the conference appearance will be accessible through the Investor Relations page of the company’s website. The company states that this communication is being provided under Regulation FD and that the information described is furnished rather than filed under federal securities laws.
UnitedHealth Group reported second quarter 2026 revenue of $112.0 billion and earnings from operations of $8.0 billion, producing a net margin of 4.9%. Diluted EPS was $6.04 and adjusted EPS $6.38. The medical cost ratio was 86.7%, compared with 89.4% a year earlier, while the operating cost ratio was 12.7%. Cash flows from operations were $11.1 billion (1.9x net income), and the debt‑to‑capital ratio stood at 41.2% as of June 30, 2026. UnitedHealthcare generated $86.0 billion of revenue and $3.9 billion of operating earnings, serving 48.5 million people, while Optum delivered $65.7 billion of revenue and $4.0 billion of operating earnings with margin expansion.
The company raised its full‑year 2026 diluted EPS outlook to $18.45–$18.95 and adjusted EPS to $19.50–$20.00, with operating cash flows projected at about $24 billion and at least $5.0 billion of share repurchases. Management highlighted ongoing reforms including a $1 billion commitment to the United Health Foundation, plans to eliminate and rebate 2026 profits from individual Affordable Care Act coverage to about 1 million members, substantial reductions in prior approval requirements, and a transparent, fee‑based pharmacy care model with a commitment to 100% pass‑through of manufacturer rebates by 2028.
UnitedHealth Group Incorporated reported the results of its 2026 Annual Meeting of Shareholders. A total of 768,066,717 shares of common stock were represented. Shareholders elected nine directors for one-year terms, with support levels generally above 89% of votes cast for each nominee.
Shareholders approved, on a non-binding basis, the Company’s executive compensation, with 559,434,838 votes for and 82.74% of votes cast in favor. They also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 95.00% of votes cast in favor. A shareholder proposal to require any board chair to be independent received 20.24% support and was not approved.
UnitedHealth Group Incorporated plans to participate in the Bank of America Securities Health Care Conference 2026. Senior leaders will answer questions in an interview-style session covering the company’s strategy, market positions, recent results and expectations for its end markets.
The session is scheduled for May 12, 2026, beginning at 11:00 a.m. Eastern Time, and a live audio webcast will be accessible through the Investor Relations page on the company’s website. The disclosure is furnished under Regulation FD and is not deemed filed or incorporated by reference into other securities law filings unless specifically referenced.
UnitedHealth Group reported first quarter 2026 revenues of $111.7 billion, up 2% year-over-year, with earnings from operations of $9.0 billion and net margin of 5.6%. Diluted earnings were $6.90 per share and adjusted earnings were $7.23 per share, both slightly above the prior year.
The medical cost ratio improved to 83.9%, down 90 basis points, while the operating cost ratio rose to 13.8% as the company invested in people, technology and modernization. Cash flows from operations were $8.9 billion, or 1.4 times net income, and the debt-to-capital ratio was 42.9% as of March 31, 2026.
Management raised its full year 2026 earnings outlook to greater than $17.35 per share and adjusted earnings to greater than $18.25 per share. During the quarter, UnitedHealth agreed to acquire Alegeus Technologies, completed the sale of the Optum UK business with $400 million in net proceeds committed to the United Health Foundation, and put in place an arrangement to repurchase at least $2.0 billion of common stock by the end of the second quarter 2026.
UnitedHealth Group Incorporated announced that senior leaders will participate in a question-and-answer interview at the Barclays 28th Annual Global Healthcare Conference. They plan to discuss the company’s strategy, market positions, recent results and expectations for its end markets. A live audio webcast will be available through the investor relations section of the company’s website.
UnitedHealth Group Incorporated has appointed Dennis Stankiewicz, age 48, as Chief Accounting Officer effective March 2, 2026. He will also continue serving as Corporate Controller, a role he has held since April 17, 2023, after joining the company in 2016 as General Auditor.
His compensation includes a $550,000 annual base salary, an initial annual cash bonus target of 85% of base salary, and eligibility for annual and long-term stock-based awards consistent with his seniority. He will receive severance equal to one times base salary if terminated without cause, conditioned on a non-compete during the severance period. The company states he has no related-party transactions requiring disclosure, while current Chief Accounting Officer Tom Roos will become Chief Financial Officer of Optum Insight on March 2, 2026.
UnitedHealth Group updated the terms of a stock option previously granted to Stephen Hemsley. The grant, originally issued on May 14, 2025 with three-year cliff vesting, now carries a two-year share holding requirement after vesting.
Hemsley must hold any net shares obtained from exercising this option until May 14, 2030, reinforcing longer-term alignment with shareholders. The only exceptions are in cases of death or disability, and all other terms of the stock option remain unchanged.
UnitedHealth Group Incorporated furnished a current report announcing that it has issued a press release with its fourth quarter and full year 2025 results. The press release is provided as Exhibit 99.1, and a hyperlinked PDF version is provided as Exhibit 99.2, both incorporated by reference in this report. The company also notes that the information under the results section is being furnished, not filed, so it is not automatically subject to certain liability provisions or incorporated into other securities law filings unless specifically referenced.
UnitedHealth Group Incorporated reports that its senior management team will meet with investors on January 12, 2026 and intends to reaffirm the company’s adjusted 2025 earnings per share expectations that were previously communicated on October 28, 2025. This indicates the company is currently standing by its earlier profit outlook for 2025.
The company also explains that its financial closing procedures for full-year 2025 are not yet complete, so actual results may change as closing activities, final adjustments, management review, and other developments occur. It cautions that final 2025 results could ultimately fall outside the previously discussed ranges, underscoring that this is a reaffirmation of expectations rather than a report of final earnings.
UnitedHealth Group Incorporated reported that its Board of Directors has appointed Scott Gottlieb, M.D. as an independent director, effective immediately. He has not yet been assigned to any Board committees.
Dr. Gottlieb is a former FDA commissioner who served from 2017 to 2019, where he focused on transparency, patient safety, medical innovation, pharmaceutical competition, the opioid crisis and youth tobacco use. He has also held positions at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee, and is a physician, a member of the National Academy of Medicine, a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates.
Dr. Gottlieb currently serves on the boards of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc. He will receive the company’s standard compensation for non-employee directors as described in UnitedHealth Group’s 2025 proxy statement, and the company will enter into its standard indemnification agreement with him.
UnitedHealth Group amended its Amended and Restated Bylaws, effective November 6, 2025. The sole purpose of the change is to reflect updates to the Company’s registered office and registered agent in the State of Delaware.
A complete copy of the Bylaws, as amended, is filed as Exhibit 3.1.
UnitedHealth Group announced that senior leaders will participate in an interview at the UBS Global Healthcare Conference 2025. The session is scheduled for Monday, November 10, 2025, at 8:45 a.m. Eastern Time.
A live audio webcast will be accessible via the Investor Relations section of the company’s website. The disclosure is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Securities Exchange Act of 1934.
UnitedHealth Group (UNH) furnished an 8-K announcing its third quarter 2025 results. The company disclosed that it issued a press release detailing Q3 2025 performance, which is provided as Exhibit 99.1 and incorporated by reference.
The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act. The filing also includes the Cover Page Interactive Data File labeled as Exhibit 104.
UnitedHealth Group reaffirmed its adjusted 2025 earnings-per-share outlook and said that the August 2025 acquisition of Amedisys is incorporated into that outlook, noting the acquisition is expected to be dilutive to adjusted EPS because of financing costs and integration investments. The company also discussed preliminary CMS Medicare Advantage star ratings for Star Year 2026/Payment Year 2027 and estimated that about 78% of its membership will be in plans rated 4 stars or higher, which the company says is consistent with expectations and historical performance. The report reiterates customary forward-looking statement cautions and lists factors that could cause actual results to differ materially.
UnitedHealth Group, Inc. filed a Current Report on Form 8-K noting that the document contains forward-looking statements about its financial prospects, operations and risks. The filing lists common examples of forward-looking language and explains that actual results may differ materially due to factors such as medical cost trends, regulatory or legal actions, cybersecurity incidents, changes in government programs, quality scores affecting revenue, contract or market risks, and other operational or financial risks. The company cautions investors not to place undue reliance on these statements and says it will not update them except as required by law.
UnitedHealth Group Incorporated reported board governance changes focused on oversight of risk and responsibility. The board created a new Public Responsibility Committee to monitor financial, regulatory, and reputational risks, including underwriting and forecasting, regulatory relationships, reputational matters, and mergers and acquisitions. Michele Hooper will chair this committee, with Charles Baker, Timothy Flynn, and Paul Garcia as members.
The company also named F. William McNabb as lead independent director, succeeding Michele Hooper, who remains on the board. In addition, UnitedHealth Group refreshed leadership and membership across its Audit and Finance, Compensation and Human Resources, Governance, and Health and Clinical Practice Policies Committees, assigning specific directors as chairs and members to each.
On 17 June 2025, UnitedHealth Group (UNH) executed an Underwriting and Pricing Agreement with BofA Securities, Barclays, Citigroup and J.P. Morgan to issue $3.0 billion of SEC-registered senior unsecured notes across four tranches: (i) $500 million 4.400% notes due 2028, (ii) $750 million 4.650% notes due 2031, (iii) $1.0 billion 5.300% notes due 2035 and (iv) $750 million 5.950% notes due 2055. The notes settled on 20 June 2025 under the company’s 2008 indenture with U.S. Bank Trust Company as trustee and were issued from automatic shelf registration statement 333-270279.
The 8-K is limited to filing transaction documents: underwriting & pricing agreements (Ex. 1.1-1.2), officers’ certificates & forms of notes (Ex. 4.1-4.4) and the Hogan Lovells legality opinion (Ex. 5.1). No changes to earnings guidance or strategy are disclosed. Proceeds are earmarked for general corporate purposes, providing additional liquidity while modestly increasing leverage and interest expense. By locking in fixed coupons out to 2055, UNH further staggers its maturity ladder at rates consistent with its large-cap investment-grade credit profile.